The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP.
Friedberg JW, et al. Among authors: young f.
Blood. 2011 Mar 10;117(10):2807-12. doi: 10.1182/blood-2010-11-314708. Epub 2011 Jan 14.
Blood. 2011.
PMID: 21239695
Free PMC article.
Clinical Trial.